I 

111TH CONGRESS 

2D SESSION H. R. 5354 

To establish an Advisory Committee on Gestational Diabetes, to provide 

grants to better understand and reduce gestational diabetes, and for 

other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 20, 2010 

Mr. ENGEL (for himself, Mr. BURGESS, Ms. DEGETTE, Mr. CASTLE, Mr. 

GENE GREEN of Texas, Mr. KING of New York, Mrs. CAPPS, Mr. GONZALEZ, Ms. BALDWIN, Mr. RANGEL, Mr. HIGGINS, Mrs. MALONEY, Mr. 

ACKERMAN, Ms. CLARKE, Ms. LEE of California, Mr. SERRANO, and Mr. 

DOYLE) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To establish an Advisory Committee on Gestational Diabetes, 

to provide grants to better understand and reduce gestational diabetes, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Gestational Diabetes 

5 Act of 2009’’ or the ‘‘GEDI Act’’. 

6 SEC. 2. FINDINGS. 

7 The Congress finds the following: 


hsrobinson on DSK69SOYB1PROD with BILLS
2 

•HR 5354 IH

1 (1) The prevalence of gestational diabetes 

2 among pregnant women in the United States is in3 creasing. 

4 (2) Gestational diabetes, which is similar to 

5 chronic forms of diabetes, normally appears at 24 to 

6 28 weeks gestation and occurs in approximately 4 to 

7 8 percent of pregnant women. 

8 (3) The associated risk factors for gestational 

9 diabetes include overweight, obesity, lack of physical 

10 activity, genetics, ethnicity, and age. 

11 (4) There is disagreement among physicians 

12 about how to treat gestational diabetes, as well as 

13 the effectiveness of current treatment regimens. 

14 (5) Gestational diabetes, which increases the 

15 risk of preeclampsia, also increases a pregnant wom16 an’s risk for developing gestational diabetes in sub17 sequent pregnancies. 

18 (6) Infants of women who develop gestational 

19 diabetes may have extreme increases in birth weight 

20 and the risks related to difficulties during the birth21 ing process, and infants born to these women— 

22 (A) may subsequently have low blood sugar 

23 or jaundice during the newborn period; 

24 (B) are at increased risk for birth trauma; 

25 and 


hsrobinson on DSK69SOYB1PROD with BILLS
3 

•HR 5354 IH

1 (C) may be at increased risk of developing 

2 type 2 diabetes and obesity as an adolescent or 

3 adult. 

4 (7) Improved nutrition and increased physical 

5 activity before, during, and after pregnancy may sig6 nificantly decrease the rates of gestational diabetes 

7 and its recurrence. 

8 (8) Obese pregnant women have a three-fold 

9 risk for the development of gestational diabetes as 

10 compared with normal weight women. 

11 SEC. 3. GESTATIONAL DIABETES. 

12 The Public Health Service Act (42 U.S.C. 201 et 

13 seq.) is amended by adding at the end the following: 

14 ‘‘TITLE XXXIII—GESTATIONAL 

15 DIABETES 

16 ‘‘SEC. 3301. UNDERSTANDING AND MONITORING GESTA17 TIONAL DIABETES DURING PREGNANCY. 

18 ‘‘(a) IN GENERAL.—The Secretary of Health and 

19 Human Services, acting through the Director of the Cen20 ters for Disease Control and Prevention, shall convene a 

21 Research Advisory Committee. 

22 ‘‘(b) MEMBERSHIP.—The members of the Research 

23 Advisory Committee— 

24 ‘‘(1) shall include— 


hsrobinson on DSK69SOYB1PROD with BILLS
4 

•HR 5354 IH

1 ‘‘(A) a representative from the Agency for 

2 Healthcare Research and Quality; 

3 ‘‘(B) a representative from the Centers for 

4 Disease Control and Prevention; 

5 ‘‘(C) a representative from the National 

6 Institutes of Health; 

7 ‘‘(D) a representative from the Office of 

8 Minority Health; 

9 ‘‘(E) a representative from the Indian 

10 Health Service; 

11 ‘‘(F) a representative from the National 

12 Center for Health Statistics; and 

13 ‘‘(G) representatives from other appro14 priate Federal agencies; and 

15 ‘‘(2) may include representatives from other ap16 propriate organizations. 

17 ‘‘(c) MATTERS TO BE STUDIED.—The Director of 

18 the Centers for Disease Control and Prevention, in con19 sultation with the Research Advisory Committee, shall de20 velop a multisite, gestational diabetes research project 

21 within the diabetes program of the Centers for Disease 

22 Control and Prevention to expand and enhance surveil23 lance data and public health research on gestational diabe24 tes. The project shall address— 


hsrobinson on DSK69SOYB1PROD with BILLS
5 

•HR 5354 IH

1 ‘‘(1) the procedures to establish accurate and 

2 efficient systems for the collection of gestational dia3 betes data within each State and commonwealth, 

4 territory, or possession of the United States; 

5 ‘‘(2) the progress of collaborative activities with 

6 the National Vital Statistics System, the National 

7 Center for Health Statistics, and State health de8 partments with respect to the standard birth certifi9 cate, in order to improve surveillance of gestational 

10 diabetes; 

11 ‘‘(3) postnatal methods of tracking women who 

12 had gestational diabetes after delivery as well as tar13 geted interventions proven to lower the incidence of 

14 type 2 diabetes in that population; 

15 ‘‘(4) variations in the distribution of diagnosed 

16 and undiagnosed diabetes, and of impaired fasting 

17 glucose tolerance and impaired fasting glucose, with18 in and among groups of women; and 

19 ‘‘(5) factors and culturally sensitive interven20 tions that influence risks and reduce the incidence of 

21 gestational diabetes during pregnancy and complica22 tions during childbirth, including cultural, behav23 ioral, racial, ethnic, geographic, demographic, socio24 economic, and genetic factors. 


hsrobinson on DSK69SOYB1PROD with BILLS
6 

•HR 5354 IH

1 ‘‘(d) MEETINGS.—Not later than 1 year after the es2 tablishment of the gestational diabetes research project 

3 under subsection (c), and annually thereafter, the Re4 search Advisory Committee shall meet to assess the 

5 progress of the project and to update the Secretary of 

6 Health and Human Services, if necessary. 

7 ‘‘(e) REPORT.—Not later than 2 years after the date 

8 of the enactment of this title, and annually thereafter, the 

9 Director of the Centers for Disease Control and Preven10 tion shall generate a report on the prevalence and trends 

11 of gestational diabetes and disseminate the report to the 

12 Secretary of Health and Human Services and appropriate 

13 Federal and non-Federal agencies. 

14 ‘‘SEC. 3302. DEMONSTRATION GRANTS TO LOWER THE RATE 

15 OF GESTATIONAL DIABETES DURING PREG16 NANCY. 

17 ‘‘(a) IN GENERAL.—The Secretary of Health and 

18 Human Services, acting through the Director of the Cen19 ters for Disease Control and Prevention, in consultation 

20 with the Research Advisory Committee established under 

21 section 3301, shall award grants, on a competitive basis, 

22 to eligible entities for demonstration projects that build 

23 capacity with key stakeholders, build new surveillance sys24 tems, and implement and evaluate evidence-based inter25 ventions to reduce the incidence of gestational diabetes 


hsrobinson on DSK69SOYB1PROD with BILLS
7 

•HR 5354 IH

1 and its recurrence and prevent type 2 diabetes after preg2 nancy. In making such grants, the Director give priority 

3 to projects focusing on— 

4 ‘‘(1) helping women who have 1 or more risk 

5 factors for developing diabetes; 

6 ‘‘(2) working with women who have had gesta7 tional diabetes during a previous pregnancy; 

8 ‘‘(3) providing postnatal care for women who 

9 had gestational diabetes; 

10 ‘‘(4) tracking cases where gestational diabetes 

11 led to the development of type 2 diabetes; 

12 ‘‘(5) educating mothers about the increased risk 

13 of their child developing diabetes; 

14 ‘‘(6) working to prevent or delay gestational di15 abetes and subsequent type 2 diabetes; and 

16 ‘‘(7) achieving outcomes designed to assess effi17 cacy and cost-effectiveness of interventions that can 

18 inform decisions on long-term sustainability, includ19 ing third-party reimbursement. 

20 ‘‘(b) APPLICATION.—An eligible entity desiring to re21 ceive a grant under this section shall submit to the Direc22 tor of the Centers for Disease Control and Prevention— 

23 ‘‘(1) an application at such time, in such man24 ner, and containing such information as the Director 

25 may require; and 


hsrobinson on DSK69SOYB1PROD with BILLS
8 

•HR 5354 IH

1 ‘‘(2) a plan to— 

2 ‘‘(A) lower the rate of gestational diabetes 

3 during pregnancy; or 

4 ‘‘(B) develop methods of tracking women 

5 who had gestational diabetes and develop effec6 tive interventions to lower the incidence of the 

7 recurrence of gestational diabetes and the devel8 opment of type 2 diabetes. 

9 ‘‘(c) USES OF FUNDS.—An entity receiving a grant 

10 under this section shall use the grant funds to carry out 

11 demonstration projects that implement evidence-based 

12 interventions to reduce the incidence of gestational diabe13 tes and its recurrence, which may include— 

14 ‘‘(1) expanding community-based health pro15 motion education, activities, and incentives focused 

16 on the prevention of gestational diabetes and type 2 

17 diabetes after pregnancy; 

18 ‘‘(2) aiding State-based diabetes prevention and 

19 control programs to collect, analyze, disseminate, 

20 and report surveillance data on women with, and at 

21 risk for, gestational diabetes and its recurrence and 

22 prevention of type 2 diabetes after pregnancy; 

23 ‘‘(3) building capacity with State-based part24 ners to implement programs and interventions to reVerDate Mar 15 2010 21:39 May 21, 2010 Jkt 089200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\H5354.IH H5354

hsrobinson on DSK69SOYB1PROD with BILLS
9 

•HR 5354 IH

1 duce the occurrence of gestational diabetes based on 

2 surveillance data; and 

3 ‘‘(4) training and encouraging health care pro4 viders— 

5 ‘‘(A) to promote risk assessment, high6 quality care, and self-management for gesta7 tional diabetes and its recurrence; and 

8 ‘‘(B) to prevent type 2 diabetes after preg9 nancy and its complications in the practice set10 tings of the health care providers. 

11 ‘‘(d) REPORTS.— 

12 ‘‘(1) CDC REPORT.—Not later than 4 years 

13 after the date of the enactment of this title, the Di14 rector of the Centers for Disease Control and Pre15 vention shall prepare and submit a report to the 

16 Secretary of Health and Human Services concerning 

17 the results of the studies conducted through the 

18 grants awarded under this section. 

19 ‘‘(2) SECRETARY REPORT.—Not later than 90 

20 days after receiving the report described in para21 graph (1), the Secretary shall prepare and submit a 

22 report to the Congress concerning the results and 

23 findings of the report. 

24 ‘‘(e) DEFINITION OF ELIGIBLE ENTITY.—In this sec25 tion, the term ‘eligible entity’ means a nonprofit organizaVerDate Mar 15 2010 21:39 May 21, 2010 Jkt 089200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6201 E:\BILLS\H5354.IH H5354

hsrobinson on DSK69SOYB1PROD with BILLS
10 

•HR 5354 IH

1 tion (such as a nonprofit academic center or community 

2 health center) or a State or local health agency. 

3 ‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There 

4 is authorized to be appropriated to carry out this section 

5 $5,000,000 for each fiscal year 2010 through 2014. 

6 ‘‘SEC. 3303. RESEARCH EXPANSION OF GESTATIONAL DIA7 BETES DURING PREGNANCY. 

8 ‘‘(a) IN GENERAL.—The Director of the Centers for 

9 Disease Control and Prevention shall conduct and support 

10 public health research regarding gestational diabetes. 

11 Such research shall include— 

12 ‘‘(1) developing and testing novel approaches 

13 for improving postpartum diabetes testing or screen14 ing and for preventing type 2 diabetes in women 

15 with a history of gestational diabetes; and 

16 ‘‘(2) conducting public health research to fur17 ther understanding of the epidemiologic, 

18 socioenvironmental, behavioral, translation, and bio19 medical factors and health systems that influence 

20 risk of gestational diabetes and progression to type 

21 2 diabetes. 

22 ‘‘(b) AUTHORIZATION OF APPROPRIATIONS.—There 

23 is authorized to be appropriated to carry out this section 

24 $5,000,000 for each fiscal year 2010 through 2014. 


hsrobinson on DSK69SOYB1PROD with BILLS
11 

•HR 5354 IH

1 ‘‘SEC. 3304. SCREENING FOR GESTATIONAL DIABETES. 

2 ‘‘The Director of the Centers for Disease Control and 

3 Prevention shall encourage postpartum screenings after 

4 gestational diabetes within the State-based diabetes pre5 vention and control programs assisted by the Centers for 

6 Disease Control and Prevention, for the purpose of reduc7 ing the incidence of gestational diabetes and its recur8 rence, progression to type 2 diabetes, and its related com9 plications.’’. 

Æ 


hsrobinson on DSK69SOYB1PROD with BILLS